This invention relates to methods, pharmaceutical compositions and kits
useful in promoting bone formation and/or preventing bone loss and
lowering blood cholesterol. The compositions are comprised of an estrogen
agonist/antagonist as a first active component and a statin as a second
active component and a pharmaceutically acceptable vehicle, carrier or
diluent. The compositions and methods of treatment are effective while
substantially reducing the concomitant liability of adverse effects
associated with estrogen administration.
